MC
LGND icon

Miles Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Miles Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3,998
Closed -$297K – 181
2016
Q2 		$297K Buy
3,998
+233
+6% +$17.3K 0.2% 112
2016
Q1 		$252K Buy
+3,765
New +$229K 0.17% 145

Other funds holding LGND

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Miles Capital's LGND Position: Q3 2016 in Review

Miles Capital sold out of Ligand Pharmaceuticals (LGND) in Q3 2016, closing a stake of 3,998 shares — an estimated $297K sold.

Miles Capital first reported a position in LGND in Q1 2016 and held it in 2 quarters. The position peaked at $297K in Q2 2016. 260 funds tracked by Wall St. Rank hold LGND as of Q3 2016.

  • Miles Capital reported no remaining Ligand Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Miles Capital sold 3,998 Ligand Pharmaceuticals shares in Q3 2016, an estimated $297K.
  • Miles Capital first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Miles Capital's Ligand Pharmaceuticals position peaked at $297K in Q2 2016.
  • 260 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2016.

Based on Miles Capital's 13F filing for Q3 2016, filed 15 Nov 2016.